Latest Breaking News On - சிறப்பு ப்ரோடொகால் மதிப்பீடுகள் - Page 1 : comparemela.com

Share this article Share this article ZUG, Switzerland, May 4, 2021 /PRNewswire/  Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the protocol titled, A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembolic Events in Patients with Metastatic Pancreatic Cancer (CATIQ P3). Isoquercetin, the Company s lead product candidate, employs a novel pathway that is based on a new mechanism of action to prevent or reverse thrombus formation with a profile that potentially conveys substantially lowered bleeding risk compared to current standard of care.  These mechanisms are related to key thrombotic pathways, including the inhibition of soluble P-selectin, which is known to help prevent or reduce thro

Jeffrey zwickerManon veraartQuercis pharmaStefan wohlfeilBeth israel deaconess medical centerDrug administrationProfessor of medicine at harvard medical schoolSpecial protocol assessmentDouble blind phaseThromboembolic eventsMetastatic pancreatic cancerAssociate professorHarvard medical schoolBenign hematologyBeth israel deaconess medicalChief medical officer